BioSpace News Archive

Exactech announced today 510(k) clearance from the U.S. Food and Drug Administration to market the TriVerse™ primary knee system.

Outset Medical, Inc. today announced that it has entered into two senior secured credit facilities with investment affiliates managed by SLR Capital Partners, LLC (“SLR”) which collectively provide for borrowings of up to $300 million.

Vistagen today announced it will host a conference call and webcast on Thursday, November 10, 2022, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report financial results for its fiscal year 2023 second quarter ended September 30, 2022.

Cambrian BioPharma announced that its CEO, James Peyer, has been selected as “BioTech Company CEO of the Year” in the second annual BioTech Breakthrough Awards, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services around the globe.

Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its third quarter financial results for the period ended September 30, 2022, on Wednesday, November 9, 2022, after the market closes.

NeuroBo Pharmaceuticals, Inc. announced the pricing of an underwritten public offering of units and a concurrent private placement for gross proceeds of approximately $30 million prior to deducting underwriting discounts and commissions and offering expenses payable by NeuroBo.

Maze Therapeutics, a company translating genetic insights into new precision medicines, today announced new research highlighting the potential of its APOL1 inhibitor program as a treatment for chronic kidney disease (CKD) and describing the role of APOL1 variants in causing and protecting from kidney disease.

Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”) today announced that it will present four abstracts and host an in-person Research & Development Day, Friday, November 11, 2022, at The Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting which will be held November 8 – 12, 2022 at the Boston Convention and Exhibition Center in Boston, MA.

Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases, today announced long-term follow-up data from the OPTIC study treating wet age-related macular degeneration (wet AMD) during The Retina Society Annual Meeting in Pasadena, California.

AMPEL BioSolutions today announced a genetic precision medicine test for lupus patients that could save lives by predicting heart disease before it happens and providing decision support for prophylactic therapies.